Colom Cristina, Rull Anna, Sanchez-Quesada José Luis, Pérez Antonio
Endocrinology and Nutrition Department, Hospital de la Santa Creu i Sant Pau-Hospital Dos de Maig, 08041 Barcelona, Spain.
Cardiovascular Biochemistry Group, Research Institute of the Hospital de la Santa Creu i Sant Pau (IIB Sant Pau), 08041 Barcelona, Spain.
J Clin Med. 2021 Apr 20;10(8):1798. doi: 10.3390/jcm10081798.
Cardiovascular disease (CVD) is a major cause of mortality in type 1 diabetes mellitus (T1DM) patients, and cardiovascular risk (CVR) remains high even in T1DM patients with good metabolic control. The underlying mechanisms remain poorly understood and known risk factors seem to operate differently in T1DM and type 2 diabetes mellitus (T2DM) patients. However, evidence of cardiovascular risk assessment and management in T1DM patients often is extrapolated from studies on T2DM patients or the general population. In this review, we examine the existing literature about the prevalence of clinical and subclinical CVD, as well as current knowledge about potential risk factors involved in the development and progression of atherosclerosis in T1DM patients. We also discuss current approaches to the stratification and therapeutic management of CVR in T1DM patients. Chronic hyperglycemia plays an important role, but it is likely that other potential factors are involved in increased atherosclerosis and CVD in T1DM patients. Evidence on the estimation of 10-year and lifetime risk of CVD, as well as the efficiency and age at which current cardiovascular medications should be initiated in young T1DM patients, is very limited and clearly insufficient to establish evidence-based therapeutic approaches to CVD management.
心血管疾病(CVD)是1型糖尿病(T1DM)患者死亡的主要原因,即使在代谢控制良好的T1DM患者中,心血管风险(CVR)仍然很高。其潜在机制仍知之甚少,而且已知的风险因素在T1DM和2型糖尿病(T2DM)患者中的作用似乎有所不同。然而,T1DM患者心血管风险评估和管理的证据往往是从对T2DM患者或普通人群的研究中推断出来的。在这篇综述中,我们研究了有关临床和亚临床CVD患病率的现有文献,以及目前关于T1DM患者动脉粥样硬化发生和发展中潜在危险因素的认识。我们还讨论了目前T1DM患者CVR分层和治疗管理的方法。慢性高血糖起着重要作用,但其他潜在因素可能也与T1DM患者动脉粥样硬化和CVD的增加有关。关于CVD 10年和终生风险的评估证据,以及目前心血管药物在年轻T1DM患者中应开始使用的有效性和年龄,非常有限,显然不足以建立基于证据的CVD管理治疗方法。